Clinical trials: sponsored by Hoffmann-La Roche
Pemphigus Vulgaris (PV)
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)
This study was designed to assess the efficacy and safety of CellCept (1 g or 1.5 g orally twice daily for 52 weeks) in patients with pemphigus vulgaris receiving prednisone or other corticosteroids.
- Trial name
- NCT00683930
- Testing
- Mycophenolate Mofetil 2 g/Day, Mycophenolate Mofetil (MMF) 3 g/Day
- Where
- 26 sites in United States, Canada and 6 more
- Volunteers
- 96 people
- Sponsor
- Hoffmann-La Roche
Post-Menopausal Osteoporosis
A Study of Bonviva (Ibandronate) and Alendronate on Renal Function in Postmenopausal Women With Osteoporosis at High Risk for Renal Disease.
This 3 arm study will evaluate renal safety after administration of an intravenous (iv) injection or infusion of Bonviva, compared to oral alendronate, in patients with postmenopausal osteoporosis, at increased risk of renal…
- Trial name
- NCT00503113
- Testing
- ibandronate [Bonviva/Boniva], Alendronate
- Where
- 44 sites in United States, Argentina and 4 more
- Volunteers
- 801 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study of Xeloda (Capecitabine) in Women With HER2-Negative Metastatic Breast Cancer
This single-arm study was designed to evaluate the efficacy and safety of oral Xeloda plus intravenous Avastin as first-line treatment in women with metastatic breast cancer.
- Trial name
- NCT00121836
- Testing
- Capecitabine, Bevacizumab
- Where
- 57 sites in United States
- Volunteers
- 109 people
- Sponsor
- Hoffmann-La Roche
Kidney Transplantation
Kidney Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Rapamune (Sirolimus) in Kidney Transplant Recipients
This 2-arm study recruited kidney transplant patients who were receiving standard care of calcineurin inhibitors (CNIs, tacrolimus or cyclosporine), CellCept (1.0-1.5 g twice daily) and corticosteroids.
- Trial name
- NCT00121810
- Testing
- mycophenolate mofetil [CellCept], Corticosteroids, Calcineurin inhibitors
- Where
- 36 sites in United States
- Volunteers
- 305 people
- Sponsor
- Hoffmann-La Roche
Peripheral Vascular Disease
A Prospective Study to Assess the Screening Value of N-terminal Pro-B-type Natriuretic Peptide (NT-proBNP) for the Identification of Patients That Benefit From Additional Cardiac Testing Prior to Vascular Surgery
The purpose of this study is to validate the screening potential of NT-proBNP for the identification of patients scheduled for vascular surgery who would benefit from additional pre-operative cardiac testing.
- Trial name
- NCT00519961
- Testing
- Elecsys®proBNP
- Where
- 2 sites in Ireland, Netherlands
- Volunteers
- 1,800 people
- Sponsor
- Hoffmann-La Roche
Colorectal Cancer
A Study of Two Different Schedules of Xeloda (Capecitabine) as First Line Therapy in Patients With Metastatic Colorectal Cancer
This 2-arm study evaluated the efficacy and safety of 2 different treatment schedules of oral Xeloda with intravenous (IV) Eloxatin (oxaliplatin) and IV bevacizumab (Avastin) as a first-line treatment in patients with locally…
- Trial name
- NCT00118755
- Testing
- capecitabine, Oxaliplatin, bevacizumab
- Volunteers
- 435 people
- Sponsor
- Hoffmann-La Roche
HIV Infections
Comparison of Ro 31-8959 Plus Zidovudine (AZT) Versus AZT Plus Zalcitabine (ddC) Versus Ro 31-8959 Plus AZT Plus ddC
PRIMARY: To determine the efficacy and toxicity of three treatment regimens: saquinavir mesylate (Ro 31-8959) plus zidovudine (AZT) vs. AZT plus zalcitabine (dideoxycytidine; ddC) vs. Ro 31-8959 plus AZT plus ddC.
- Trial name
- NCT00001040
- Testing
- Saquinavir, Zidovudine, Zalcitabine
- Where
- 10 sites in United States
- Volunteers
- 300 people
- Sponsor
- Hoffmann-La Roche
Liver Transplantation
Liver Spare the Nephron (STN) Study - A Study of CellCept (Mycophenolate Mofetil) and Sirolimus in Recipients of a Liver Transplant
This two-arm study will assess the efficacy and safety of a long-term calcineurin inhibitor-free maintenance regimen with CellCept and sirolimus in recipients of an orthotropic liver transplant.
- Trial name
- NCT00118742
- Testing
- mycophenolate mofetil [CellCept], Tacrolimus, Cyclosporine
- Where
- 46 sites in United States, Canada
- Volunteers
- 293 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection
This 2-arm study will compare the efficacy and safety of treatment with Pegasys (180 µg weekly) plus Copegus (800 mg daily) and Pegasys (180 µg weekly) plus Copegus (1000-1200 mg daily) in interferon-naive patients with CHC…
- Trial name
- NCT00353418
- Testing
- Peginterferon alfa-2a, Ribavirin
- Volunteers
- 415 people
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A Study of Induction Dosing With PEGASYS (Peginterferon Alfa-2a [40KD]) Plus Copegus in Treatment-Naive Patients With Chronic Hepatitis C
This 4-arm study will compare the efficacy and safety of PEGASYS induction and maintenance dosing, versus standard fixed dosing in combination with Copegus, and the efficacy and safety of higher dose versus standard dose Copegus…
- Trial name
- NCT00394277
- Testing
- peginterferon alfa-2a, Ribavirin
- Where
- 184 sites in United States, Belgium and 13 more
- Volunteers
- 1,175 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis
This 3 arm study will compare the safety and efficacy, with regard to reduction of signs and symptoms, of tocilizumab versus placebo, both in combination with methotrexate (MTX).
- Trial name
- NCT00106548
- Testing
- tocilizumab [RoActemra/Actemra], Methotrexate
- Where
- 74 sites in Argentina, Australia and 15 more
- Volunteers
- 623 people
- Sponsor
- Hoffmann-La Roche
Rheumatoid Arthritis
A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.
This 2 arm study will investigate the pharmacokinetics of simvastatin and methotrexate in combination with tocilizumab to assess any potential drug interactions.
- Trial name
- NCT00365001
- Testing
- tocilizumab [RoActemra/Actemra], Methotrexate, Simvastatin
- Where
- 11 sites in United States, New Zealand
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Male Osteoporosis
The Effect Of Oral Ibandronate In Male Osteoporosis
Male osteoporosis is a common and important clinical problem, associated with significant morbidity, mortality and societal expense. Approximately 10% of men =65 years of age are osteoporotic.
- Trial name
- STRONG (NCT00397839)
- Testing
- Ibandronate
- Where
- 41 sites in United States
- Volunteers
- 135 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of NeoRecormon (Epoetin Beta) in Patients With End Stage Renal Disease.
This single arm study will determine the effects of complete anemia correction in anemic patients with end-stage renal disease currently receiving suboptimal doses of NeoRecormon.
- Trial name
- NCT00413101
- Testing
- epoetin beta [NeoRecormon]
- Where
- Serbia
- Volunteers
- 50 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of NeoRecormon in Patients With Chronic Kidney Disease.
This 2 arm study will compare the level of anemia, and the decline in renal function, between patients receiving NeoRecormon, and those not receiving it.
- Trial name
- NCT00437723
- Testing
- epoetin beta [NeoRecormon]
- Where
- 2 sites in Serbia
- Volunteers
- 90 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Lamivudine Resistant HBeAg-Negative Chronic Hepatitis B.
This single arm study will evaluate the efficacy and safety of PEGASYS in patients with lamivudine resistant HBeAg negative chronic hepatitis B. Patients will receive PEGASYS 180 micrograms s.c.
- Trial name
- NCT00460850
- Testing
- peginterferon alfa-2a (40KD) [PEGASYS]
- Where
- 4 sites in Turkey (Türkiye)
- Volunteers
- 60 people
- Sponsor
- Hoffmann-La Roche
Myasthenia Gravis, Generalized
A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Controlling Symptoms of Myasthenia Gravis
The efficacy and safety of CellCept (1g po, bid for 36 weeks) will be assessed in patients with myasthenia gravis receiving prednisone, or other corticosteroids.
- Trial name
- NCT00683969
- Testing
- mycophenolate mofetil (CellCept)
- Where
- 43 sites in United States, Canada and 12 more
- Volunteers
- 136 people
- Sponsor
- Hoffmann-La Roche
Myasthenia Gravis Generalised
A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.
This 2 arm study will provide optional continuation of double-blind treatment with CellCept or placebo, in patients with myasthenia gravis who have achieved good symptom control in study WX17798.
- Trial name
- NCT00408213
- Testing
- mycophenolate mofetil [CellCept]
- Where
- 16 sites in United States, France and 5 more
- Volunteers
- 136 people
- Sponsor
- Hoffmann-La Roche
Anemia
A Study of NeoRecormon (Epoetin Beta) in Patients With Renal Anemia.
This study will determine whether 8 weekly monitoring of hemoglobin and iron parameters in the correction phase of NeoRecormon therapy in patients with renal anemia is as safe and effective as 4 weekly monitoring.
- Trial name
- NCT00440063
- Testing
- epoetin beta [NeoRecormon]
- Where
- 9 sites in Australia
- Sponsor
- Hoffmann-La Roche
Kidney Transplantation
A Study of CellCept (Mycophenolate Mofetil) in Kidney Transplant Patients Switched From EC-MPS.
This study will assess the safety, efficacy and effect on quality of life of switching kidney transplant patients from reduced dose EC-MPS treatment due to gastrointestinal problems to a higher than the equimolar dose of…
- Trial name
- NCT00420472
- Testing
- mycophenolate mofetil [CellCept]
- Where
- 7 sites in Germany
- Sponsor
- Hoffmann-La Roche